$180.3 M

MBII Mkt cap, 18-Oct-2018

$10.1 M

Marrone Bio Innovations Revenue Q2, 2018
Marrone Bio Innovations Net income (Q2, 2018)-7.8 M
Marrone Bio Innovations EBIT (Q2, 2018)-10 M
Marrone Bio Innovations Cash, 30-Jun-201823.3 M
Marrone Bio Innovations EV159.6 M

Marrone Bio Innovations Income Statement

Annual

USDFY, 2013Y, 2014FY, 2015FY, 2016

Revenue

14.5m1.1m9.8m14.0m

Revenue growth, %

(92%)793%43%

General and administrative expense

18.5m

Operating expense total

18.5m

EBIT

(29.0m)(15.5m)(39.5m)(23.7m)

EBIT margin, %

(200%)(1416%)(403%)(168%)

Interest expense

6.0m669.0k2.8b2.9m

Interest income

49.0k17.0k51.0m37.0m

Pre tax profit

(28.5m)(16.2m)(43.7m)(31.1m)

Income tax expense

Net Income

(28.5m)(16.2m)(43.7m)(31.1m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

1.3m2.8m3.6m2.1m3.4m2.5m2.7m5.0m3.6m4.2b6.5b4.2m4.3m10.1m

R&D expense

4.5m

General and administrative expense

4.5m6.3m6.0m7.9m7.4m5.3m5.5m4.5m3.8m5.3b5.1b5.2m5.0m9.7m

Operating expense total

8.9m10.6m10.3m11.3m10.7m8.8m7.9m6.8m6.4m7.8b7.9b8.3m7.6m14.8m

Depreciation and amortization

1.5m

EBIT

(8.7m)(9.5m)(9.5m)(11.3m)(10.4m)(8.6m)(7.5m)(4.9m)(5.3m)(5.9b)(5.4b)(6.6m)(5.5m)(10.0m)

EBIT margin, %

(645%)(340%)(261%)(547%)(309%)(348%)(279%)(97%)(145%)(142%)(84%)(156%)(127%)(99%)

Interest expense

1.1m773.0k825.0k669.0k659.0k687.0k1.0m759.0k755.0k636.0m869.0m804.0k1.1m1.5m

Interest income

24.0k10.0k11.0k9.0k6.0k14.0k15.0k10.0k8.0k1.0m

Pre tax profit

(6.1m)(10.2m)(10.4m)(11.9m)(11.0m)(9.8m)(9.3m)(6.8m)(7.2m)(7.6b)(7.4b)(8.5m)

Income tax expense

Net Income

(6.1m)(10.2m)(10.4m)(11.9m)(11.0m)(9.8m)(9.3m)(6.8m)(7.2m)(7.6b)(7.4b)(8.5m)(2.9m)(7.8m)

Marrone Bio Innovations Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

24.5m35.3m19.8m9.6m

Accounts Receivable

6.2m1.8m2.3m3.6m

Inventories

1.7m1.3m1.3m8.5m

Current Assets

58.7m54.7m36.0m26.9m

PP&E

9.4m20.2m18.4m17.3m

Total Assets

68.9m77.2m71.8m46.0m

Accounts Payable

4.5m5.8m2.0m1.4m

Short-term debt

Current Liabilities

11.7m31.2m12.9m15.2m

Long-term debt

Total Liabilities

76.2m

Preferred Stock

Additional Paid-in Capital

147.2m193.1m201.6m204.5m

Retained Earnings

(105.4m)(159.8m)(203.6m)(234.6m)

Total Equity

41.8m33.2m(2.0m)(30.2m)

Financial Leverage

1.6 x2.3 x-35.5 x-1.5 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

40.8m21.3m57.6m22.4m12.2m27.8m9.8m21.2m16.0m1.8m10.2m3.7m14.8m23.3m

Accounts Receivable

2.1m7.2m4.1m2.2m3.0m1.4m4.7m4.5m2.1m8.1m5.8m1.9m4.4m4.7m

Inventories

10.8m12.8m12.5m11.8m10.6m9.8m8.6m8.0m8.4m8.1m8.4m9.3m10.0m9.2m

Current Assets

68.6m47.0m80.1m41.1m30.2m43.4m28.1m37.8m30.6m24.4m29.6m19.5m30.4m38.0m

PP&E

5.7m15.8m18.5m20.1m20.1m19.3m19.1m18.5m17.9m16.9m16.5m16.2m15.7m15.3m

Total Assets

75.4m63.5m101.0m63.4m52.5m80.1m64.0m58.2m50.2m43.0m47.8m37.4m48.0m55.1m

Accounts Payable

5.1m8.6m5.2m4.1m3.2m1.0m2.6m2.2m2.2m3.0m3.2m2.7m2.6m1.5m

Short-term debt

1.7m1.9m2.6m

Current Liabilities

10.2m14.5m11.4m28.6m27.7m11.5m13.4m13.8m12.6m18.6m21.7m28.1m11.6m10.4m

Total Debt

1.7m1.9m2.6m

Total Liabilities

25.0m29.5m36.0m41.0m40.0m72.0m74.7m74.9m73.5m80.2m83.5m81.1m34.3m33.2m

Additional Paid-in Capital

145.9m149.6m191.1m194.2m195.3m200.6m202.2m202.9m203.6m205.1m214.0m214.5m279.9m293.0m

Retained Earnings

(95.4m)(115.7m)(126.1m)(171.8m)(182.7m)(192.5m)(212.9m)(219.6m)(226.8m)(242.3m)(249.7m)(258.2m)(266.2m)(271.0m)

Total Equity

50.4m34.0m65.0m22.4m12.5m8.1m(10.7m)(16.7m)(23.2m)(37.2m)(35.6m)(43.7m)13.8m22.0m

Financial Leverage

1.5 x1.9 x1.6 x2.8 x4.2 x9.9 x-6 x-3.5 x-2.2 x-1.2 x-1.3 x-0.9 x3.5 x2.5 x

Marrone Bio Innovations Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(28.5m)(16.2m)(43.7b)(31.1m)

Depreciation and Amortization

976.0k2.2m

Accounts Receivable

(3.4m)1.8m(1.2m)

Inventories

(6.8m)1.3m582.0k

Accounts Payable

1.7m5.8m(588.0k)

Cash From Operating Activities

(34.0m)(15.5m)(24.3m)

Purchases of PP&E

(4.0m)(209.0k)

Cash From Investing Activities

(17.7m)(209.0k)

Long-term Borrowings

(9.4m)(260.0k)

Cash From Financing Activities

66.1m14.3m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(6.1m)(10.2m)(10.4m)(11.9m)(22.9m)(32.7m)(9.3m)(16.1m)(23.3m)(7.6b)(2.9m)(7.8m)

Depreciation and Amortization

833.0k1.7m2.6m594.0k1.2m1.7m478.0k983.0k

Accounts Receivable

7.2m4.1m(383.0k)(1.2m)398.0k(2.3m)(2.2m)292.0k8.1m(567.0k)(937.0k)

Inventories

869.0k2.0m2.9m504.0k1.1m659.0k(220.0k)646.0k

Accounts Payable

8.6m5.2m(1.6m)(2.3m)(4.4m)583.0k196.0k223.0k3.0m(1.1m)(2.2m)

Cash From Operating Activities

(11.4m)(20.4m)(28.7m)(9.7m)(13.5m)(18.3m)(9.7m)(14.9m)

Purchases of PP&E

(1.0m)(1.4m)(1.5m)(49.0k)(93.0k)(169.0k)(362.0k)(478.0k)

Cash From Investing Activities

(1.0m)(1.4m)(1.5m)(49.0k)(93.0k)(169.0k)(362.0k)(478.0k)

Long-term Borrowings

(97.0k)(192.0k)(371.0k)(65.0k)(129.0k)(195.0k)(67.0k)(129.0k)

Cash From Financing Activities

(589.0k)(1.3m)22.7m(253.0k)14.7m24.1m37.5m

Interest Paid

2.1m2.5m

Income Taxes Paid

Marrone Bio Innovations Ratios

USDY, 2018

EV/EBIT

-16 x

EV/CFO

-10.7 x

Financial Leverage

2.5 x
Report incorrect company information